616 related articles for article (PubMed ID: 33435520)
21. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
22. A new promising candidate to overcome drug resistant herpes simplex virus infections.
Zinser E; Krawczyk A; Mühl-Zürbes P; Aufderhorst U; Draßner C; Stich L; Zaja M; Strobl S; Steinkasserer A; Heilingloh CS
Antiviral Res; 2018 Jan; 149():202-210. PubMed ID: 29155164
[TBL] [Abstract][Full Text] [Related]
23. Synergistic inhibition of herpesvirus replication by docosanol and antiviral nucleoside analogs.
Marcelletti JF
Antiviral Res; 2002 Nov; 56(2):153-66. PubMed ID: 12367721
[TBL] [Abstract][Full Text] [Related]
24. An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection.
Park PJ; Antoine TE; Farooq AV; Valyi-Nagy T; Shukla D
Invest Ophthalmol Vis Sci; 2013 Sep; 54(9):6373-81. PubMed ID: 23989188
[TBL] [Abstract][Full Text] [Related]
25. Antiviral activity of PHA767491 against human herpes simplex virus in vitro and in vivo.
Hou J; Zhang Z; Huang Q; Yan J; Zhang X; Yu X; Tan G; Zheng C; Xu F; He S
BMC Infect Dis; 2017 Mar; 17(1):217. PubMed ID: 28320320
[TBL] [Abstract][Full Text] [Related]
26. Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor.
Yajima M; Yamada H; Takemoto M; Daikoku T; Yoshida Y; Long T; Okuda T; Shiraki K
Antiviral Res; 2017 Mar; 139():95-101. PubMed ID: 28027917
[TBL] [Abstract][Full Text] [Related]
27. Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.
Okuda T; Kurokawa M; Matsuo K; Honda M; Niimura M; Shiraki K
J Med Virol; 2004 Jan; 72(1):112-20. PubMed ID: 14635018
[TBL] [Abstract][Full Text] [Related]
28. Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor.
Schneider SM; Pritchard SM; Wudiri GA; Trammell CE; Nicola AV
mBio; 2019 May; 10(3):. PubMed ID: 31088925
[TBL] [Abstract][Full Text] [Related]
29. [Anti alpha-herpesvirus drugs].
Koshizuka T; Suzutani T
Nihon Rinsho; 2012 Apr; 70(4):558-63. PubMed ID: 22568134
[TBL] [Abstract][Full Text] [Related]
30. Characterization of DNA polymerase-associated acyclovir-resistant herpes simplex virus type 1: mutations, sensitivity to antiviral compounds, neurovirulence, and in-vivo sensitivity to treatment.
Wang LX; Takayama-Ito M; Kinoshita-Yamaguchi H; Kakiuchi S; Suzutani T; Nakamichi K; Lim CK; Kurane I; Saijo M
Jpn J Infect Dis; 2013; 66(5):404-10. PubMed ID: 24047739
[TBL] [Abstract][Full Text] [Related]
31. Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence.
Omura N; Fujii H; Yoshikawa T; Yamada S; Harada S; Inagaki T; Shibamura M; Takeyama H; Saijo M
Virol J; 2017 Mar; 14(1):59. PubMed ID: 28320407
[TBL] [Abstract][Full Text] [Related]
32. Topical formulations containing Trichilia catigua extract as therapeutic options for a genital and an acyclovir-resistant strain of herpes recurrent infection.
Ribelato EV; Wouk J; Celestino GG; Rodrigues BCD; Darido MLG; Barboza MGL; Botura TJ; de Oliveira MC; de Andrade FG; Lonni AASG; de Mello JCP; da Rocha SPD; Faccin-Galhardi LC
Braz J Microbiol; 2023 Sep; 54(3):1501-1511. PubMed ID: 37338788
[TBL] [Abstract][Full Text] [Related]
33. NSC23766 and Ehop016 Suppress Herpes Simplex Virus-1 Replication by Inhibiting Rac1 Activity.
Zhang F; Liu Y; You Q; Yang E; Liu B; Wang H; Xu S; Nawaz W; Chen D; Wu Z
Biol Pharm Bull; 2021 Sep; 44(9):1263-1271. PubMed ID: 34162786
[TBL] [Abstract][Full Text] [Related]
34. Antifungal drug ciclopirox olamine reduces HSV-1 replication and disease in mice.
Bernier KM; Morrison LA
Antiviral Res; 2018 Aug; 156():102-106. PubMed ID: 29908958
[TBL] [Abstract][Full Text] [Related]
35. The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice.
LeBlanc RA; Pesnicak L; Godleski M; Straus SE
J Infect Dis; 1999 Sep; 180(3):594-9. PubMed ID: 10438344
[TBL] [Abstract][Full Text] [Related]
36. Phenoxazine derivatives suppress the infections caused by herpes simplex virus type-1 and herpes simplex virus type-2 intravaginally inoculated into mice.
Hayashi K; Hayashi T; Miyazawa K; Tomoda A
J Pharmacol Sci; 2010; 114(1):85-91. PubMed ID: 20736512
[TBL] [Abstract][Full Text] [Related]
37. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals.
van Velzen M; van Loenen FB; Meesters RJ; de Graaf M; Remeijer L; Luider TM; Osterhaus AD; Verjans GM
J Infect Dis; 2012 May; 205(10):1539-43. PubMed ID: 22457282
[TBL] [Abstract][Full Text] [Related]
38. Preparation of a monoPEGylated derivative of cyanovirin-N and its virucidal effect on acyclovir-resistant strains of herpes simplex virus type 1.
Lei Y; Chen W; Liang H; Wang Z; Chen J; Hong H; Xie L; Nie H; Xiong S
Arch Virol; 2019 May; 164(5):1259-1269. PubMed ID: 30903291
[TBL] [Abstract][Full Text] [Related]
39. Harmol used for the treatment of herpes simplex virus induced keratitis.
Xu H; Zhou N; Huang Z; Wu J; Qian Y
Virol J; 2024 May; 21(1):118. PubMed ID: 38802860
[TBL] [Abstract][Full Text] [Related]
40. Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes.
Rose R; Brunnemann AK; Baukmann S; Bühler S; Fickenscher H; Sauerbrei A; Zell R; Krumbholz A
Antiviral Res; 2021 Nov; 195():105166. PubMed ID: 34419483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
